The estimated Net Worth of Judy R Joice is at least $556 Tausend dollars as of 14 May 2021. Ms Joice owns over 60,137 units of Durect Corp stock worth over $149,101 and over the last 11 years she sold DRRX stock worth over $0. In addition, she makes $406,510 as Sr. VP of Operations & Corp. Quality Assurance at Durect Corp.
Ms has made over 2 trades of the Durect Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 60,137 units of DRRX stock worth $45,704 on 14 May 2021.
The largest trade she's ever made was exercising 60,137 units of Durect Corp stock on 14 May 2021 worth over $45,704. On average, Ms trades about 9,830 units every 29 days since 2014. As of 14 May 2021 she still owns at least 94,969 units of Durect Corp stock.
You can see the complete history of Ms Joice stock trades at the bottom of the page.
Judy R. Joice is the Sr. VP of Operations & Corp. Quality Assurance at Durect Corp.
As the Sr. VP of Operations & Corp. Quality Assurance of Durect Corp, the total compensation of Ms Joice at Durect Corp is $406,510. There are 3 executives at Durect Corp getting paid more, with Dr. James E. Brown D.V.M. having the highest compensation of $775,884.
Ms Joice is 64, she's been the Sr. VP of Operations & Corp. Quality Assurance of Durect Corp since . There are 2 older and 2 younger executives at Durect Corp. The oldest executive at Durect Corp is Dr. Su Il Yum Ph.D., 82, who is the Exec. Officer.
Judy's mailing address filed with the SEC is C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO, CA, 95014.
Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management... und Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Durect Corp executives and other stock owners filed with the SEC include: